Quantifying Viral Vector Yield Losses Downstream

In this segment from the Bioprocess Online Live event, "Downstream Decisions To Maximize Viral Vector Yields And Reduce COGs," panelists Hung Trinh, Ph.D., CEO at Vertex Biopharm Consulting, and Nathalie Clément, Ph.D., senior VP of vector development at Siren Biotechnology, contextualize the kind of losses seen in downstream viral vector purification, which can sometimes be as high as 80%.